Ureteral Stent-Related Dysfunction
Conditions
Interventions
mirabegron :Patients were randomly divided into two groups, this group of patients treated with mirabegron (50 mg/day).
doxazosin:Patients were randomly divided into two groups, this group of patients treated with doxazosin (4 mg/day)
Sponsors
Kunming Health Commission
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult male or female patients > 18 years of age with urinary calculi confirmed by imaging (CT or ultrasound) and requiring transurethral ureteral lithotripsy and ureteral stent implantation.
Exclusion criteria
Exclusion criteria: 1. History of overactive bladder, interstitial cystitis, pelvic pain, or pelvic surgery; 2. Patients with severe gynecological diseases, malignant tumors, heart and lung failure, or severe infection and shock symptoms; 3. Patients with psychiatric disorders; 4. BMI >=40 kg/m²; 5. Long-term use of contraceptive pills, digoxin, nebivolol, propranolol, and nadolol (known to interfere with ß3AR signaling); 6. Patients continuously receiving sildenafil or other PDE5 inhibitors; 7. Participants in any other interventional trials; 8. Patients unable to provide informed consent (those under legal guardianship); 9. Drug contraindications (such as hypersensitivity reactions).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ureteral stent symptom; | — |
Countries
China
Contacts
Public ContactBo Tao
The Affiliated Anning First People's Hospital, Kunming University of Science and Technology,
Outcome results
None listed